Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ.

Clin Chem. 2008 Jan;54(1):53-60. Epub 2007 Nov 16.

2.

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ.

Clin Chem. 2008 Jan;54(1):44-52. Epub 2007 Nov 2.

3.

Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.

Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J.

BMC Cancer. 2009 Aug 19;9:287. doi: 10.1186/1471-2407-9-287.

4.

Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.

Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z.

Dis Markers. 2003-2004;19(4-5):185-95.

5.

SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.

Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikström P.

Int J Cancer. 2007 Aug 1;121(3):615-20.

6.

Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.

Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ.

Clin Cancer Res. 2005 Feb 1;11(3):1073-85.

7.
8.

Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.

Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD.

Clin Chem. 2005 Apr;51(4):695-707. Epub 2005 Feb 3.

9.

A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.

Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, Potter JD, Winget M, Thornquist M, Feng Z.

Biostatistics. 2003 Jul;4(3):449-63.

10.

SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.

Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW.

Prostate. 2007 Oct 1;67(14):1565-75.

PMID:
17705230
11.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L.

Clin Chem. 2005 Jan;51(1):102-12.

12.
13.

Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.

Al-Ruwaili JA, Larkin SE, Zeidan BA, Taylor MG, Adra CN, Aukim-Hastie CL, Townsend PA.

Cancer Genomics Proteomics. 2010 Mar-Apr;7(2):93-103.

PMID:
20335524
14.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
15.

Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.

Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J, Zhang L.

Cancer. 2008 Feb 1;112(3):544-51.

16.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

17.

Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.

Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR.

Laryngoscope. 2008 Jan;118(1):61-8.

PMID:
18043497
18.

[Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].

Pan YZ, Xiao XY, Zhao D, Zhang L, Ji GY, Li Y, He DC, Zhao XJ, Yang BX.

Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3172-5. Chinese.

PMID:
16405834
19.

SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.

Cheng L, Zhou L, Tao L, Zhang M, Cui J, Li Y.

J Cancer Res Clin Oncol. 2008 Jul;134(7):769-76. doi: 10.1007/s00432-007-0344-4. Epub 2008 Jan 17.

PMID:
18202856
20.
Items per page

Supplemental Content

Write to the Help Desk